Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...

Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with sales now heading into reverse, the company is looking to extend its franchise.

Biogen Inc. (NASDAQ:BIIB) shares tumbled to a 52-week low of $139.7, reflecting a stark downturn in the biotechnology firm's market performance. With a market capitalization of $20.38 billion and a ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...

The FDA and EMA have both accepted Biogen’s applications for a higher dose regimen of Spinraza (nusinerse) for spinal muscular atrophy (SMA). According to the company, the regimen includes a faster ...

Biogen's officials expressed optimism about the potential benefits this regimen could offer to SMA patients and their families. The DEVOTE study, which evaluated the higher dose regimen's safety ...

Biogen BIIB reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.44, which beat the Zacks Consensus Estimate ...

The Muscular Dystrophy Association celebrates this new more accessible treatment option for people living with SMA. MDA - New ...

(RTTNews) - Biogen Inc. (BIIB) announced Thursday that ... a higher dose regimen of nusinersen for spinal muscular atrophy (SMA). The higher dose regimen of nusinersen comprises a more rapid ...

Biotech giant Biogen Inc (NASDAQ:BIIB) is scheduled to report fourth-quarter earnings on 12 February. The Wall Street ...

Biogen reported fourth-quarter 2024 earnings that surpassed analysts' expectations, driven by strong sales of new product ...